MDPI and ACS Style
DÃaz-Tejedor, A.; RodrÃguez-Ubreva, J.; Ciudad, L.; Lorenzo-Mohamed, M.; González-RodrÃguez, M.; Castellanos, B.; Sotolongo-Ravelo, J.; San-Segundo, L.; Corchete, L.A.; González-Méndez, L.;
et al. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands. Int. J. Mol. Sci. 2024, 25, 4718.
https://doi.org/10.3390/ijms25094718
AMA Style
DÃaz-Tejedor A, RodrÃguez-Ubreva J, Ciudad L, Lorenzo-Mohamed M, González-RodrÃguez M, Castellanos B, Sotolongo-Ravelo J, San-Segundo L, Corchete LA, González-Méndez L,
et al. Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands. International Journal of Molecular Sciences. 2024; 25(9):4718.
https://doi.org/10.3390/ijms25094718
Chicago/Turabian Style
DÃaz-Tejedor, Andrea, Javier RodrÃguez-Ubreva, Laura Ciudad, Mauro Lorenzo-Mohamed, Marta González-RodrÃguez, Bárbara Castellanos, Janet Sotolongo-Ravelo, Laura San-Segundo, Luis A. Corchete, Lorena González-Méndez,
and et al. 2024. "Tinostamustine (EDO-S101), an Alkylating Deacetylase Inhibitor, Enhances the Efficacy of Daratumumab in Multiple Myeloma by Upregulation of CD38 and NKG2D Ligands" International Journal of Molecular Sciences 25, no. 9: 4718.
https://doi.org/10.3390/ijms25094718